http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen (AMGN) Submits Sotorasib NDA To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
-
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
-
Amgen's (AMGN) Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic NSCLC Patients With KRAS G12C Mutation
-
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
-
Amgen And Novartis Partner With Karamo Brown To Support And Empower People Living With Migraine
-
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
-
Amgen (AMGN) and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities
-
Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities
-
Amgen To Webcast Investor Call At ASH 2020
-
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
-
Amgen (AMGN) Announces New Data Being Presented At ASH 2020
-
Amgen Announces New Data Being Presented At ASH 2020
-
Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
-
Cytokinetics (CYTK) Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen (AMGN)
-
Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
-
Amgen To Present At The Jefferies Virtual London Healthcare Conference
-
Amgen To Present At The Cowen 4th Annual IO Summit
-
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
-
Amgen Showcases New Data Across Cardiovascular Portfolio At AHA Scientific Sessions 2020: A Virtual Experience
-
Amgen Presents First Clinical Data for AMG 757 at SITC 2020
-
Amgen To Present At The 29th Annual Credit Suisse Healthcare Conference
-
Amgen Reports Third Quarter 2020 Financial Results
-
Amgen Announces Webcast Of 2020 Third Quarter Financial Results
-
Amgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program
-
Amgen Announces 2020 Fourth Quarter Dividend
-
Amgen (AMGN), Cytokinetics (CYTK) And Servier Announce Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure Achieved Primary Composite Efficacy Endpoint, No Reduction in Secondary
-
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
-
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
-
Amgen (AMGN) Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced NSCLC
-
Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer
-
Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine
-
Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine
-
Lilly (LLY) and Amgen (AMGN) Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
-
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
-
Amgen To Webcast Investor Calls At ESMO 2020
-
Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020
-
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
-
Amgen To Present At The 2020 Bank of America Virtual Global Healthcare Conference
-
Amgen To Present At The 18th Annual Morgan Stanley Global Healthcare Conference
-
Amgen To Present At The 15th Annual Citi BioPharma Conference
-
Amgen (AMGN) Reports Positive Data from Phase 3B Study of Repatha (Evolocumab) in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
-
Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020
-
New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations
-
Ligand (LGND) Announces Amgen's (AMGN) KYPROLIS Approved by FDA as Combination Regimen with DARZALEX and Dexamethasone in for Patients with R/R Multiple Myeloma
-
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple
-
Amgen (AMGN) Announces FDA Approves New KYPROLIS Combination Regimen With DARZALEX And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens
-
FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens
-
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
-
Amgen Reports Second Quarter 2020 Financial Results
-
Amgen Announces Webcast Of 2020 Second Quarter Financial Results
